Let's talk about RET, a fascinating receptor tyrosine kinase protein with a vital role in our development and cell growth. While it's normally beneficial, when RET signaling goes awry, it can lead to uncontrolled growth and cancer. Today, we'll dive into RET fusions, a rare but significant event in lung cancer. These fusions, discovered in 2012, have paved the way for targeted therapies. Two FDA-approved selective RET inhibitors, selpercatinib and pralsetinib, have shown impressive response rates and brain efficacy, offering hope for patients. Join us as we explore these groundbreaking treatments and their potential to revolutionize lung cancer care.
Discussion of RET begins at 24:20 in this YouTube video from the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage, on Saturday, July 15, 2023 hosted by GRACE - Global Resource for Advancing Cancer Education.